Research ExplorerPublicationsTwo Pituitary Neuroendocrine Tumors (PitNETs) with Very High...

Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?

Standard

Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC? / Saeger, Wolfgang; Mawrin, Christian; Meinhardt, Matthias; Wefers, Annika K; Jacobsen, Frank.

In: ENDOCR PATHOL, Vol. 33, No. 2, 06.2022, p. 257-262.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Saeger, W, Mawrin, C, Meinhardt, M, Wefers, AK & Jacobsen, F 2022, 'Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?', ENDOCR PATHOL, vol. 33, no. 2, pp. 257-262. https://doi.org/10.1007/s12022-021-09693-y

APA

Saeger, W., Mawrin, C., Meinhardt, M., Wefers, A. K., & Jacobsen, F. (2022). Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC? ENDOCR PATHOL, 33(2), 257-262. https://doi.org/10.1007/s12022-021-09693-y

Vancouver

Saeger W, Mawrin C, Meinhardt M, Wefers AK, Jacobsen F. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC? ENDOCR PATHOL. 2022 Jun;33(2):257-262. https://doi.org/10.1007/s12022-021-09693-y

Bibtex

@article{56637932858f403b84d57a0433ddc3cd,
title = "Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?",
abstract = "We report two pituitary neuroendocrine tumors (PitNETs) with very high Ki67 labeling indices, many mitoses and TP53 mutation (nearly all tumor cell nuclei were positive for p53). One of the tumors had bone and liver metastases. One was a corticotroph cell tumor; the other was a lactotroph tumor. The classification of these tumors is the subject of this discussion. Traditionally, pituitary carcinomas are only diagnosed by demonstration of metastases according to the 2017 WHO classification. In contrast, neuroendocrine neoplasms of the gastrointestinal tract and pancreas are classified as either well differentiated NETs that are graded as G1, G2, and G3 based on proliferation as determined by Ki67 indices of ≤ 3, 3-20 and > 20%, and/or < 2, 2-20, and > 20 mitoses per 10 high-power field respectively, or as neuroendocrine carcinomas (NECs) that are poorly differentiated neoplasms with mitoses > 20/HPF and/or a Ki67 index > 20%. With the reclassificiation of PitNETs, in our opinion, the adequate term for the well-differentiated corticotroph tumor that we report is a PitNET G3, whereas the undifferentiated prolactin tumor should be classified as PitNEC. This report expands the spectrum of pituitary neuroendocrine neoplasms.",
author = "Wolfgang Saeger and Christian Mawrin and Matthias Meinhardt and Wefers, {Annika K} and Frank Jacobsen",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
month = jun,
doi = "10.1007/s12022-021-09693-y",
language = "English",
volume = "33",
pages = "257--262",
journal = "ENDOCR PATHOL",
issn = "1046-3976",
publisher = "Humana Press",
number = "2",

}

RIS

TY - JOUR

T1 - Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?

AU - Saeger, Wolfgang

AU - Mawrin, Christian

AU - Meinhardt, Matthias

AU - Wefers, Annika K

AU - Jacobsen, Frank

N1 - © 2021. The Author(s).

PY - 2022/6

Y1 - 2022/6

N2 - We report two pituitary neuroendocrine tumors (PitNETs) with very high Ki67 labeling indices, many mitoses and TP53 mutation (nearly all tumor cell nuclei were positive for p53). One of the tumors had bone and liver metastases. One was a corticotroph cell tumor; the other was a lactotroph tumor. The classification of these tumors is the subject of this discussion. Traditionally, pituitary carcinomas are only diagnosed by demonstration of metastases according to the 2017 WHO classification. In contrast, neuroendocrine neoplasms of the gastrointestinal tract and pancreas are classified as either well differentiated NETs that are graded as G1, G2, and G3 based on proliferation as determined by Ki67 indices of ≤ 3, 3-20 and > 20%, and/or < 2, 2-20, and > 20 mitoses per 10 high-power field respectively, or as neuroendocrine carcinomas (NECs) that are poorly differentiated neoplasms with mitoses > 20/HPF and/or a Ki67 index > 20%. With the reclassificiation of PitNETs, in our opinion, the adequate term for the well-differentiated corticotroph tumor that we report is a PitNET G3, whereas the undifferentiated prolactin tumor should be classified as PitNEC. This report expands the spectrum of pituitary neuroendocrine neoplasms.

AB - We report two pituitary neuroendocrine tumors (PitNETs) with very high Ki67 labeling indices, many mitoses and TP53 mutation (nearly all tumor cell nuclei were positive for p53). One of the tumors had bone and liver metastases. One was a corticotroph cell tumor; the other was a lactotroph tumor. The classification of these tumors is the subject of this discussion. Traditionally, pituitary carcinomas are only diagnosed by demonstration of metastases according to the 2017 WHO classification. In contrast, neuroendocrine neoplasms of the gastrointestinal tract and pancreas are classified as either well differentiated NETs that are graded as G1, G2, and G3 based on proliferation as determined by Ki67 indices of ≤ 3, 3-20 and > 20%, and/or < 2, 2-20, and > 20 mitoses per 10 high-power field respectively, or as neuroendocrine carcinomas (NECs) that are poorly differentiated neoplasms with mitoses > 20/HPF and/or a Ki67 index > 20%. With the reclassificiation of PitNETs, in our opinion, the adequate term for the well-differentiated corticotroph tumor that we report is a PitNET G3, whereas the undifferentiated prolactin tumor should be classified as PitNEC. This report expands the spectrum of pituitary neuroendocrine neoplasms.

U2 - 10.1007/s12022-021-09693-y

DO - 10.1007/s12022-021-09693-y

M3 - SCORING: Journal article

C2 - 34669159

VL - 33

SP - 257

EP - 262

JO - ENDOCR PATHOL

JF - ENDOCR PATHOL

SN - 1046-3976

IS - 2

ER -